Myeloid Cure
Pioneering Leader in
Macrophage Immunotherapy
About Myeloid Cure
Myeloid Cure
As a high-tech research and development center, Myeloid Cure is committed to original innovation, focusing on the development and industrialization of novel macrophage targets and original immunotherapeutics within the disease immune microenvironment. The company has independently built an innovative macrophage immunotherapy pipeline, deploying a differentiated First-in-Class and Me-only pipeline matrix across two major areas—autoimmune diseases and malignant tumors—to establish robust technological barriers. To date, the company has filed 18 patent applications, including 12 invention patents, and has been granted 14 patents, including 8 invention patents. As the body's first line of innate immune defense, macrophages are harnessed by the company to reprogram the disease immune microenvironment through functional modulation, with the potential to address the limitations of existing immunotherapies and set a new benchmark for the treatment of major related diseases.
Backed by its outstanding innovation capabilities and development potential, the company has earned numerous government recognitions:
"5213" Industrialization Excellence
Project Support Program
National-level Technology-based SME
Zhejiang Provincial Technology-based SME
Zhejiang Provincial "Specialized, Refined,
Distinctive, and Innovative" SME
Hangzhou Municipal Enterprise High-Tech
Research and Development Center
Pipeline
Product Pipeline
Myeloid Cure has established more than 10 R&D pipelines of significant commercial value, most of which are world-first monoclonal and bispecific antibody projects.
MS003 is a therapeutic monoclonal antibody for autoimmune diseases such as inflammatory bowel disease (IBD), treating various diseases by mobilizing macrophages to clear over-activated T cells. The MS003 pipeline is expected to enter Phase I clinical trials in early 2027.
MS032 is the first drug candidate from the Myeloid Phagocytosis Engager (MPE) bispecific antibody platform independently developed by Myeloid Cure. Myeloid Cure's MPE offers unique technological advantages, efficiently clearing target cells—including primary B cells and various tumor cells—through a dual mechanism that simultaneously enhances Fcγ receptor (FcγR)-mediated antibody-dependent cellular phagocytosis (ADCP) and ADCP-independent phagocytosis. With its deeper target-cell clearance capability, MS032 is poised to set a new benchmark in the treatment of autoimmune diseases and malignant tumors, offering patients treatment options of greater clinical value. The MS032 pipeline is expected to file for IND in 2027.
| Pipeline | Strategy/Indication | Target Validation | Molecular Confirmation | In Vivo Efficacy | IND Enabling | IND Submission | Clinical Stage |
| MS003 | Macrophages eliminate T cell IBD |
|
|||||
| MS032 | Macrophages eliminate B cell Autoimmune diseases / Tumor |
|
|||||
News
Myeloid Cure News
2026-05-13
Myeloid Cure and MSD Launch Clinical Co-Development of Antibody Therapies in Autoimmune Diseases
On May 12, 2026, Myeloid Cure is hnonored to announce the signing of a joint development cooperation agreement with the MSD R&D China Innovation Collaboration Center. The two parties will collaborate on the clinical co-development of antibody therapeutics in the autoimmune disease space.
2026-04-02
Myeloid Cure Completes Over RMB 150 Million Series A Financing, Deepens Original Drug Development in Macrophage Immunotherapy
Myeloid Cure Biotechnology Co., Ltd. ("Myeloid Cure") announced the completion of its over RMB 150 million Series A financing. The round is led by Bayland Capital, with participation from Hongfeng Investment, Ruihua Capital, leading industry investment institutions and prominent industrial funds.
2025-11-11
Myeloid Cure Invited to Inaugural MSD R&D China Science Day, Signs Letter of Intent with MSD R&D China
Beijing, China, November 11, 2025 — Today, MSD China R&D Center successfully hosted the inaugural MSD R&D China Science Day in Beijing. The event brought together guests from research institutes, medical institutions, biotech enterprises and the financial sector to explore
2022-09-13
Dedicated to Novel Target and Drug R&D, China’s First Innovative Biopharma Focused on Macrophages Myeloid Cure Completes Another Tens of Millions of RMB Financing
Myeloid Cure Biotechnology Co., Ltd. recently announced the completion of a new round financing of tens of millions of RMB. Myeloid Cureis the pioneer emerging biotechnology enterprise focusing on the development of biopharmaceuticals with new targets for macrophages in the tumor microenvironment and autoimmune diseases in China
2021-06-21
Myeloid Cure announced the completion of an angel round of financing of tens of millions of RMB
Myeloid Cure is the pioneer domestic emerging biotechnology enterprise in China focusing on the development of new target drugs for macrophages. Immunotherapy drugs are currently the most important treatments for cancers and autoimmune diseases,